Palisade Bio, Inc. - Common Stock PALI 深 沪
等待开盘 09-18 09:30:00 美东时间
0.5775
-0.025
-4.13%
华盛通- 最 高0.6591
- 今 开0.612
- 成交量 1086.87万股
- 最 低 0.5465
- 昨 收 0.6024
- 总市值 276.95万
- 52周最高 4.318
- 市盈率 静 --
- 换手率 226.64%
- 52周最低 0.53
- 委 比 -96.23%
- 总股本 479.56万
- 历史最高 18405.00
- 量 比 45.29
- 振 幅 18.69%
- 历史最低 0.53
- 每 手 1
- 风险率 2.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio Releases PALI-2108 Phase 1b Clinical Data Demonstrating 100% Clinical Response Regarding Efficacy Of PALI-2108 In Ulcerative Colitis
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concernsPhase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in
09-17 21:05
Palisades Goldcorp Updates on Capital Transaction and Warrants
Palisades Goldcorp Ltd. ( ($TSE:PALI) ) has provided an announcement. Palisades...
09-10 10:07
Palisade Bio Receives Health Canada Clearance To Initiate Phase 1b Study Of PALI-2108 In Fibrostenotic Crohn's Disease
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesPatient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026Continued
09-05 20:47
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio received Health Canada’s No Objection Letter for a Phase 1b clinical study of PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor for fibrostenotic Crohn’s disease (FSCD). FSCD lacks approved anti-fibrotic therapies, with current treatments addressing symptoms rather than the disease process. The open-label study will enroll 6-12 patients to assess safety, pharmacokinetics, pharmacodynamics, and exploratory endpoints...
09-05 12:45
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). Dr. Feagan discussed the challenges with current FSCD treatments and highlighted the need for more effective therapies addressing both inflammation and fibrosis. He shared insights on PALI-2108, a novel localized approach aiming to reduce class-asso...
08-25 13:00
Palisade Bio Reports Phase 1 Results For PALI-2108, Showing Safety And Strong Colon Tissue Drug Levels As Company Prepares For Phase 2 Trial In 2026
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic
08-07 21:16
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
Palisade Bio announced positive data for their novel drug PALI-2108 in treating ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). The Phase 1b study showed 100% clinical response in UC patients, with significant reductions in inflammation and improved histology. Additionally, the Phase 1a study demonstrated sustained drug levels in colon tissue, supporting once-daily dosing. The company plans to submit a Phase 2 IND application in...
08-07 13:15
Palisade Bio Secures China Patent For PALI-2108, A Targeted PDE4 Inhibitor For Crohn's Disease And Ulcerative Colitis
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needsInflammatory
07-31 20:46
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor for fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. The patent, titled “Gut Microbiota-Activated PDE4 Inhibitor Prodrug,” will cover claims on the composition of matter for PALI-2108 in China wi...
07-31 12:45
Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in pre-market...
07-24 17:23
